Turning Point Therapeutics 配当と自社株買い

配当金基準チェック /06

Turning Point Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.4%

バイバック利回り

総株主利回り	-0.4%
将来の配当利回り	0%
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Jul 21

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Mar 23

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Dec 06

The Take On Turning Point Therapeutics

Dec 03

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Aug 15

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Aug 04

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Jun 17

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 08

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Feb 26

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Jan 29

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Jan 22

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Dec 08

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Nov 12

決済の安定と成長

配当データの取得

安定した配当: TPTXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: TPTXの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Turning Point Therapeutics 配当利回り対市場

TPTX 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (TPTX)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.2%
業界平均 (Biotechs)	2.3%
アナリスト予想 (TPTX) (最長3年)	0%

注目すべき配当: TPTXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: TPTXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: TPTXの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: TPTXが配当金を報告していないため、配当金の持続可能性を計算できません。

Turning Point Therapeutics 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index

Turning Point Therapeutics, Inc. Announces Executive Changes

Consensus forecasts updated

Turning Point Therapeutics, Inc. Provides Operational and Clinical Update

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Executive VP & CFO recently sold US$89k worth of stock

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Biotechnology Index

Price target decreased to US$79.50

Price target decreased to US$87.71

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Turning Point Therapeutics, Inc. (NasdaqGS:TPTX) for $3.8 billion.

Consensus forecasts updated

Turning Point Therapeutics, Inc. Announces Appointment of Steve Sabus as Chief Commercial Officer, Effective as of May 31, 2022

Price target decreased to US$105

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

Turning Point Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Turning Point Therapeutics, Inc. Announces Positive Topline Results from the Registrational TRIDENT-1 Study Across All Four ROS1-Positive Advanced Non-Small Cell Lung Cancer Cohort

Turning Point Therapeutics, Inc. Appoints Brian Sun as Senior Vice President and General Counsel, Effective April 11, 2022

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Turning Point Therapeutics, Inc. Announces the Resignation of Siegfried Reich as Executive Vice President and Chief Scientific Officer

Full year 2021 earnings: EPS exceeds analyst expectations

Price target decreased to US$119

Turning Point Therapeutics, Inc. Announces Retirement of Annette North as Executive Vice President, General Counsel and Corporate Secretary, Effective March 4, 2022

President recently sold US$108k worth of stock

Turning Point Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for Combination of Elzovantinib and Aumolertinib in Egfr Mutant Met-Amplified Non-Small Cell Lung Cancer

Turning Point Therapeutics, Inc. Provides Updates and Anticipates 2022 Clinical and Discovery Pipeline Milestones

Turning Point Therapeutics, Inc. Announces Regulatory Updates for Its Lead Drug Candidate, Repotrectinib, ROS1/TRK Inhibitor, and for Elzovantinib (TPX-0022), Its Drug Candidate Targeting MET, CSF1R and SRC

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

The Take On Turning Point Therapeutics

Price target decreased to US$134

Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference

Executive VP exercised options and sold US$630k worth of stock

Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

Consensus revenue estimates increase to US$30.4m

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Executive VP & Chief Commercial Officer recently sold US$140k worth of stock

Chairman of the Board recently bought US$163k worth of stock

Turning Point Therapeutics, Inc. Grants FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Executive VP exercised options and sold US$900k worth of stock

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Senior VP of Finance & Administration and Principal Accounting Officer has left the company

Consensus forecasts updated

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Turning Point Therapeutics, Inc. Appoints Brian Baker as the Interim Principal Financial Officer

Turning Point Therapeutics, Inc. Announces Executive Changes, Effective March 31, 2021

Analysts update estimates

New 90-day low: US$103

Earnings beat expectations, revenue disappoints

Turning Point Therapeutics, Inc. Provides Operational and Clinical Updates

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Turning Point Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

President exercised options and sold US$8.1m worth of stock

New 90-day high: US$140

Price target raised to US$160

Turning Point Therapeutics Reports Updated Interim Data from Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Price target raised to US$141

We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Turning Point Therapeutics, Inc. Announces the Following 2021 Milestone Targets for Its Pipeline

New 90-day high: US$131

Executive VP & Chief Medical Officer exercised options and sold US$657k worth of stock

Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers

Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

New 90-day high: US$126

Analysts update estimates

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Turning Point Therapeutics, Inc. Announces the Resignation of Carl Gordon from the Board of Directors of the Company

Analysts update estimates

Revenue beats expectations, earnings disappoint

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Price target raised to US$92.11

New 90-day high: US$92.56

配当金基準チェック /06